Structure and stereochemistry of the active metabolite of clopidogrel

Drug Metabolism and Disposition

Volumn 30, Issue 11, 2002, Pages 1288-1295

  Pereillo, Jean Marie ^a   Maftouh, Mohamed ^a   Andrieu, Alain ^a   Uzabiaga, Marie Francoise ^a   Fedeli, Olivier ^a   Savi, Pierre ^a   Pascal, Marc ^a   Herbert, Jean Marc ^a   Maffrand, Jean Pierre ^a   Picard, Claudine ^a  

^a NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [1 (2 CHLOROPHENYL) 2 METHOXY 2 OXOETHYL] 4 SULFANYL 3 PIPERIDINYLIDENE]ACETIC ACID; 2 OXOCLOPIDROGEL; CLOPIDOGREL; DRUG METABOLITE; UNCLASSIFIED DRUG; ACRYLONITRILE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

ARTICLE; BIOTRANSFORMATION; CHIRALITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INDICATION; DRUG STRUCTURE; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; STEREOCHEMISTRY; STEREOISOMERISM; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG EFFECT; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; THROMBOCYTE;

ACRYLONITRILE; BIOTRANSFORMATION; BLOOD PLATELETS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PLATELET AGGREGATION INHIBITORS; STEREOISOMERISM; TICLOPIDINE;

EID: 18644372477     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.11.1288     Document Type: Article

References (13)

1. CAPRIE Steering Committee (1996) A randomised, blinded, trial of SR25990C versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348:1329-1339.
2. Feliste R, Delebassée D, Simon MF, Chap H, Derfreyn G, Vallée E, Douste-Blazy L, and Maffrand JP (1987) Broad-spectrum antiplatelet activity of PCR5332 and PCR4099 involves the suppression of the effects of released ADP. Thromb Res 48:403-415.
3. Herbert JM, Frehel D, Bernat A, Badorc A, Savi P, Delebassée D, Kieffer G, Defreyn G, and Maffrand JP (1993a) Clopidogrel hydrogenosulfate. Drug Future 18:107-112.
4. Herbert JM, Frehel D, Vallée E, Kieffer G, Gouy D, Necciari J, Defreyn G, and Maffrand JP (1993b) A novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 11:180-198.
5. Herbert JM, Savi P, and Maffrand JP (1999) Biochemical and pharmacological properties of Clopidogrel: A new ADP receptor antagonist. Eur Heart J 1 (Suppl A):A31-A40.
6. Kazui M, Ishizuka T, Yamamura A, Kurihara A, Naganuma, Iwabuchi H, Takahashi M, Kawabata K, Yoneda K, Kita J, et al. (2001) Mechanism for production of pharmacologically active metabolites of CS-747, a new pro-drug ADP-receptor antagonist. XVIIIth Congress of the International Society of Thrombosis and Haemostasis: 2001 July 6-12; Paris, France. pp 1916, The International Society of Thrombosis and Haemostasis, Chapel Hill, North Carolina.
7. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, and Herbert JM (1994b) The antiaggregating activity of Clopidogrel is due to a metabolic activation by hepatic cytochrome P450-1A. Thromb Haemostasis 72:313-317.
8. Savi P, Herbert JM, Pflieger AM, Dol F. Delebassée D, Combalbert J, Defreyn G, and Maffrand JP (1992) Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine Clopidogrel. Biochem Pharmacol 44:527-532.
9. 12, a new platelet ADP receptor, target of Clopidogrel. Biophys Biochem Res Commun 283:379-383.
10. Savi P, Laplace MC, Maffrand JP, and Herbert JM (1994a) Binding of [3H]-2-methylthio ADP to rat platelets: Effect of Clopidogrel and ticlopidine. J Pharmacol Exp Ther 269:772-777.
11. Savi P, Pereillo JM, Uzabiaga F, Combalbert J, Picard C, Maffrand JP, Pascal M, and Herbert JM (2000) Identification and biological activity of the active metabolite of Clopidogrel. Thromb Haemostasis 84:891-896.
12. Sugidachi A, Asai F, Ogawa T, Inoue T, and Koike H (2000) The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. B J Pharmacol 129:1439-1446.
13. Sugidachi A, Asai F, Yoneda K, Iwmura R, Ogawa T, Otsuguro K, and Koike H (2001) Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type Gi-linked antagonist, CS-747. B J Pharmacol 132:47-54.